The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S. workforce. The New ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan TOKYO, Mar 5, 2025 - (J ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...

Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...